Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

News

Inquiries

PB004 project – first administration in a Phase 0 clinical trial

18 July

2024

PB004 project – first administration in a Phase 0 clinical trial

Pure Biologics announces the first administration of drug candidate PBA-0405 in a Phase 0 (first-in-human) clinical trial.

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

17 July

2024

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

Pure Biologics has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase 0 clinical trial in Project PB003G for the PBA-0111 molecule.

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

22 December

2023

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

Pure Biologics has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase 0 clinical trial in Project PB004 for the PBA-0405 molecule.

eIND submission for the PB004 project and further development of PB003G towards Phase 0

21 November

2023

eIND submission for the PB004 project and further development of PB003G towards Phase 0

Pure Biologics submits an eIND application to the FDA for the start of Phase 0 in the PB004 project and decides on the further development of PB003G toward Phase 0.

13 September

2023

Development plans to the end of 2024

Pure Biologics summarizes implementation and updates Development Plans through the end of 2024.

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

18 December

2023

Nationale Nederlanden PTE – the largest institutional investor in the CEE region, joins the shareholder base of multiQure

PB004 project – first administration in a Phase 0 clinical trial

PB003G project – the FDA approval to proceed with Phase 0 clinical trial

PB004 project – the FDA approval to proceed with Phase 0 clinical trial

eIND submission for the PB004 project and further development of PB003G towards Phase 0

Development plans to the end of 2024

Zapytanie Ofertowe – 00007/00008_ABM_02/2023

Zapytanie Ofertowe – 00007/00008_ABM_01/2023

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020